Roivant Sciences ( (ROIV) ) has shared an announcement.
Roivant Sciences Ltd. has unveiled mosliciguat, a groundbreaking inhaled treatment for pulmonary hypertension associated with interstitial lung disease, showing promising results in Phase 1b trials with substantial reductions in pulmonary vascular resistance. This once-daily therapy delivered via a dry powder inhaler is well-tolerated and may offer a differentiated approach to treatment due to its unique mechanism as a soluble Guanylate Cyclase (sGC) activator. With a significant patient population in need and limited existing treatments, mosliciguat represents not only a potential medical breakthrough but also a significant commercial opportunity for Roivant.
See more data about ROIV stock on TipRanks’ Stock Analysis page.
